Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Sarcoma, Ewing 2Osteosarcoma 2Neuroblastoma 2Rhabdoid Tumor 1Osteosarcoma Recurrent 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Melanoma 1Medulloblastoma 1Lymphoma, Follicular 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Breast Neoplasms 1Astrocytoma 1

Interventions

Rituximab 25Lenalidomide 21Cyclophosphamide 20Prednisone 14obinutuzumab 12Vincristine 12Doxorubicin 11Magnetic Resonance Spectroscopy 10Bendamustine Hydrochloride 9Specimen Handling 8ibrutinib 7Biopsy 7fludarabine 6pembrolizumab 5fludarabine phosphate 5Radiotherapy 5Peripheral Blood Stem Cell Transplantation 5zanubrutinib 4venetoclax 4tazemetostat 4Whole-Body Irradiation 4R-CHOP protocol 4Prednisolone 3Mycophenolic Acid 3Etoposide 3Cyclosporine 3tisagenlecleucel 2polatuzumab vedotin 2orelabrutinib 2loncastuximab tesirine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × Eflornithine × 90 days × Clear all
NCT07468136 2026-04-13

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

Mayo Clinic

Phase 1/2 Not yet recruiting
33 enrolled
CNSLymphoid

Astrocytoma, Glioblastoma, Glioma, Lymphoma, Follicular, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡